LONDON (Alliance News) - Epistem Holdings PLC Monday said a number of its directors, including Chief Executive Matthew Walls, acquired 228 shares each in the company.
The stem cell company said the shares were acquired as a result of the subscription for partnership shares and the award of matching shares, under its July 13, 2009, share investment plan.
Wall's shareholding now stands at 10,600 shares, or 0.11% of the company.
Financial Director John Rylands now has 194,853 shares, or 2.01%.
Managing Director, Contract Research Services, Catherine Booth has 984,955 shares, or 10.17%, while Managing Director, Novel Therapies, has 14,280 shares, or 0.15%.
The transactions occurred on July 30 at a 583 pence, August 30 at 560 pence, and September 27 at 383 pence.
Epistem shares were Monday quoted at 328.5 pence, down 1.5 pence, or 0.5%.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2013 Alliance News Limited. All Rights Reserved.
